Working…
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered SARS-CoV-2.
Protect yourself and others from infection by washing your hands, wearing masks or using an alcohol based rub frequently and not touching your face.

CUReD:  CSIR Ushered Repurposed Drugs -  A website that provides information on CSIR Partnered Clinical Trials.

   Details of Plasma Therapy

Name of trial AN OPEN LABEL RANDOMISED CONTROL TRIAL ON PASSIVE IMMUNIZATION WITH CONVALESCENT PLASMA IN SEVERE COVID-19 DISEASE (PICP19)
CSIR lab/s involved Industry Sponsor/s & Scientific Collaborator/s Clinical Trial Site/s
CSIR-Indian Institute of Chemical Biology (IICB), Kolkata

NA

 ID & BG Hospital (COVID Hospital), Beleghata, WB, Kolkata, WB
Type of Intervention Convalescent Plasma
IP Status of Drug/s  Validated on Clinical Samples
Mechanism of Action & Scientific rationale for Covid-19
Passive immunization using convalescent plasma is an age-old therapeutic strategy in infections for which no vaccine or drugs with roven efficacy are available. Our aim is to study convalescent plasma therapy in an open label randomised control trial, which involves administration of plasma from patients who have recovered from COVID-19 infection to patients with severe COVID-19 disease, with or without mild or moderate acute respiratory distress syndrome.
Combinations therapy or monotherapy  Plasma therapy
Trial design

Health Condition / Problems Studied

 Health Type Condition

Inclusion criteria:
Patients (aged >18 years, <80 years) hospitalized with RT-PCR proven COVID-19 with severe disease (fever or suspected respiratory infection, plus one of the following; respiratory rate >30 breaths/min, severe respiratory distress, SpO2< 90% at room air) with Mild ARDS (200 mmHg < PaO2/FiO2 ≤ 300 mmHg, with PEEP or CPAP ≥5 cm H2O, or non-ventilated) or Moderate ARDS (100 mmHg < PaO2/FiO2 ≤200 mmHg, with PEEP ≥5 cm H2O, or non-ventilated) within 5 to 10 days from initial presentation

Exclusion criteria:                                          
1. Pregnant mothers
2. Patients with age less than 18 years
3. Admitted late after 10 days of initial presentation
4. Patients refusing consent

  

Number of trial sites       

Number of arms              

Number of patients         

01
02
80

Click here for End points (primary and secondary)
Status of the CSIR trial Completed (Results)
Name & details of Clinical PI/s

Dr. Dipyaman Ganguly, MBBS, PhD, PhD
(PI and Coordinator)
Principal Scientist

CSIR-Indian Institute of Chemical Biology, Kolkata

Prof. Prasun Bhattacharya, MBBS, MD
Professor & Head, Dept. of Immunohematology & Blood Transfusion, Medical College Hospitals, Kolkata

Prof. BibhutiSaha, MBBS, MD
Professor & Head, Dept. of Tropical Medicine, School of Tropical Medicine, Kolkata

Prof. Biswanath Sharma Sarkar, MBBS, MD
Professor & Head, Department of Medicine, ID & BG Hospital, Kolkata

 
Dr. Yogiraj Ray, MBBS, MD, DM (Trial site Investigator)
Assistant Professor, Calcutta School of Tropical Medicine & ID and BG Hospital, Kolkata

Dr. Shekar Ranjan Paul, MBBS, DPH, DTCD
Senior Resident,ID & BG Hospital, Kolkata

Dr. Sandip Paul, PhD
Ramanujan Fellow,CSIR-Indian Institute of Chemical Biology, Kolkata.

Dr. Shilpak Chatterjee, PhD

Senior Scientist, CSIR - Indian Institute of Chemical Biology, Kolkata.

Back